TaiMed Biologics Inc. (4147.TWO)
TWD 82.5
(-0.48%)
TWD 82.5
(-0.48%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 491.77 Million | 563 Million | 413.44 Million | 722.48 Million | 704.5 Million | 241.04 Million |
| Cost of Revenue | 266.54 Million | 347.29 Million | 329.48 Million | 401.24 Million | 474.49 Million | 260.89 Million |
| Gross Profit | 225.23 Million | 215.71 Million | 83.95 Million | 321.24 Million | 230.01 Million | -19.85 Million |
| Operating Expenses | 225.23 Million | 407.56 Million | 570.32 Million | 454 Million | 620 Million | 300.92 Million |
| Selling, General and Administrative Expenses | 97.18 Million | 74.44 Million | 109.72 Million | 59.55 Million | 44.17 Million | 42.62 Million |
| Research and Development Expenses | 294.27 Million | 333.12 Million | 460.6 Million | 394.44 Million | 575.83 Million | 440.39 Million |
| Other Expenses | - | -71.67 Million | 18.84 Million | -54.93 Million | -188.3 Million | -925 Thousand |
| Cost and Expenses | 658 Million | 754.86 Million | 899.8 Million | 855.24 Million | 1.09 Billion | 561.82 Million |
| Operating Income | -166.23 Million | -259.19 Million | -463.48 Million | -179.21 Million | -578.29 Million | -320.78 Million |
| Interest Expense | 14.81 Million | 10.09 Million | 7.44 Million | 4.08 Million | 356 Thousand | 6000.00 |
| Income Tax Expense | - | 10.09 Million | 7.44 Million | 4.08 Million | 356 Thousand | -925 Thousand |
| Earnings before Tax | -194.81 Million | -269.28 Million | -470.93 Million | -183.3 Million | -578.65 Million | -321.71 Million |
| Net Income | -194.81 Million | -279.38 Million | -478.37 Million | -187.39 Million | -579.01 Million | -321.71 Million |
| Earnings Per Share Basic | -0.76 | -1.09 | -1.87 | -0.73 | -2.26 | -1.28 |
| Earnings Per Share Diluted | -0.76 | -1.09 | -1.87 | -0.73 | -2.26 | -1.28 |
| Weighted Average Shares Outstanding | 256.5 Million | 256.04 Million | 255.94 Million | 255.87 Million | 255.69 Million | 250.73 Million |
| Weighted Average Shares Outstanding (Diluted) | 256.5 Million | 256.04 Million | 255.94 Million | 255.87 Million | 255.69 Million | 250.73 Million |
| Gross Margin | 0.46 | 0.38 | 0.20 | 0.44 | 0.33 | -0.08 |
| EBIT Margin | -0.05 | -0.18 | -0.74 | -0.05 | -0.69 | -1.07 |
| Profit Margin | -0.40 | -0.50 | -1.16 | -0.26 | -0.82 | -1.33 |
| EBITDA | -25.23 Million | -103.36 Million | -307.45 Million | -40.05 Million | -486.69 Million | -258.9 Million |
| Earnings Before Tax Margin | -0.34 | -0.46 | -1.12 | -0.25 | -0.82 | -1.33 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 146.94 Million | 178.94 Million | 491.77 Million | 158.21 Million | 157.55 Million | 104.24 Million |
| Cost of Revenue | 100.87 Million | 125.49 Million | 266.54 Million | 89.1 Million | 80.21 Million | 70.36 Million |
| Gross Profit | 46.06 Million | 53.45 Million | 225.23 Million | 69.1 Million | 77.33 Million | 33.88 Million |
| Operating Expenses | 87.31 Million | 90.5 Million | 391.46 Million | 95.6 Million | 80.62 Million | 99.18 Million |
| Selling, General and Administrative Expenses | 3.39 Million | 3.81 Million | - | 19.26 Million | 20.85 Million | 18.01 Million |
| Research and Development Expenses | 83.92 Million | 86.68 Million | - | 76.34 Million | 59.77 Million | 81.16 Million |
| Other Expenses | 6.11 Million | 21.61 Million | -391.46 Million | -95.6 Million | -589 Thousand | 19.25 Million |
| Cost and Expenses | 188.19 Million | 215.99 Million | 658 Million | 184.71 Million | 160.84 Million | 169.54 Million |
| Operating Income | -41.25 Million | -37.05 Million | -166.23 Million | -26.49 Million | -2.1 Million | -44.09 Million |
| Interest Expense | 2.9 Million | 3.7 Million | 14.81 Million | 3.75 Million | 3.77 Million | 3.75 Million |
| Income Tax Expense | - | 38.55 Million | -13.76 Million | -30.03 Million | 38.74 Million | 38.7 Million |
| Earnings before Tax | -27.53 Million | -16.03 Million | -194.81 Million | -60.28 Million | -5.87 Million | -47.84 Million |
| Net Income | -27.53 Million | -16.03 Million | -194.81 Million | -60.28 Million | -5.87 Million | -47.84 Million |
| Earnings Per Share Basic | -0.10 | -0.06 | - | -0.23 | -0.02 | -0.19 |
| Earnings Per Share Diluted | -0.10 | -0.06 | - | -0.23 | -0.02 | -0.19 |
| Weighted Average Shares Outstanding | 273.07 Million | 253.48 Million | 256.5 Million | 256.63 Million | 256.63 Million | 256.43 Million |
| Weighted Average Shares Outstanding (Diluted) | 273.07 Million | 253.48 Million | 256.5 Million | 256.63 Million | 256.63 Million | 256.43 Million |
| Gross Margin | 0.31 | 0.30 | 0.46 | 0.44 | 0.49 | 0.33 |
| EBIT Margin | -0.02 | 0.01 | - | -0.11 | 0.23 | -0.05 |
| Profit Margin | -0.19 | -0.09 | -0.40 | -0.38 | -0.04 | -0.46 |
| EBITDA | -2.74 Million | 1.55 Million | - | -17.8 Million | 36.59 Million | -5.26 Million |
| Earnings Before Tax Margin | -0.28 | -0.21 | -0.34 | -0.17 | -0.01 | -0.42 |
DLHC
AMIGF
AET
7337
ZKIN
4130